Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

about

Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients.

P2860

Q47554082-A39354CE-0AC9-4B94-9E12-86008269FA2A

P2860

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

Item

http://www.wikidata.org/entity/Q39301797

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

@en

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

@nl

type

Item

label

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

@en

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

@nl

prefLabel

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

@en

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

@nl

P1476

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use

@en

P2093

Caterina Uberti-Foppa

http://www.w3.org/2001/XMLSchema#string

Giulia Morsica

http://www.w3.org/2001/XMLSchema#string

Sabrina Bagaglio

http://www.w3.org/2001/XMLSchema#string

P2860

Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications

Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target

Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank

P2888

s40265-017-0753-x

P304

1043-1055

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-017-0753-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giulia Morsica

Caterina Uberti-Foppa

Sabrina Bagaglio

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28497432

http://www.w3.org/2001/XMLSchema#string

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

about

P2860

P2860

Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698